Advanced botulinum toxin
Treatment of muscle groups beyond the three licensed upper-face areas — the lower face, neck, masseter and sweat glands — where technique rests on anatomical reasoning rather than product licensing.
Advanced botulinum toxin is the working label for everything beyond the licensed upper-face indications: glabellar complex, lateral canthal lines and frontalis.
The distinction is regulatory rather than pharmacological. The molecule behaves the same way wherever it is placed — it blocks acetylcholine release at the neuromuscular junction, the muscle weakens over several days, and function returns as new nerve terminals sprout. What changes off the licensed areas is that dose, dilution and injection points are not specified by a marketing authorisation, so they come from published technique papers and anatomical study instead.
That shifts the burden onto the practitioner. In the lower face the muscles are smaller, more superficial and more functionally loaded — the same units that soften a chin dimple can weaken the depressor labii and produce visible asymmetry when smiling. Masseter treatment carries a longer horizon still, since sustained reduction changes bite mechanics.
Off-label is not the same as unevidenced, and it is not the same as unregulated: it means the evidence lives in the literature rather than the product label, and the practitioner is the one accountable for having read it.
